MGMT Promoter Methylation Testing to Predict Survival in Glioblastoma Treated With Temozolomide
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
MGMT Promoter Methylation Testing to Predict Overall Survival in People With Glioblastoma Treated With Temozolomide: A Comprehensive Meta-Analysis Based on a Cochrane Systematic Review
Neuro-oncology 2021 Sep 01;23(9)1457-1469, S Brandner, A McAleenan, C Kelly, F Spiga, HY Cheng, S Dawson, L Schmidt, CL Faulkner, C Wragg, S Jefferies, JPT Higgins, KM KurianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.